Endologix, Inc. (ELGX) Receives $26.75 Average Target Price from Brokerages

Endologix, Inc. (NASDAQ:ELGX) has received a consensus recommendation of “Hold” from the eight research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $22.75.

ELGX has been the subject of a number of recent research reports. ValuEngine raised Endologix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research lowered Endologix from a “hold” rating to a “sell” rating in a report on Monday, March 11th. BTIG Research reissued a “buy” rating on shares of Endologix in a report on Tuesday, February 26th. Finally, Stifel Nicolaus set a $7.00 price objective on Endologix and gave the stock a “hold” rating in a report on Monday, April 1st.

In other Endologix news, CFO Vaseem Mahboob bought 15,128 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The shares were purchased at an average price of $6.61 per share, for a total transaction of $99,996.08. Following the purchase, the chief financial officer now directly owns 76,820 shares of the company’s stock, valued at $507,780.20. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John Onopchenko bought 30,257 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The stock was acquired at an average price of $6.61 per share, for a total transaction of $199,998.77. Following the purchase, the chief executive officer now directly owns 96,360 shares in the company, valued at $636,939.60. The disclosure for this purchase can be found here. Insiders bought a total of 48,410 shares of company stock worth $319,990 in the last 90 days. Company insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citigroup Inc. boosted its stake in shares of Endologix by 279.2% in the 4th quarter. Citigroup Inc. now owns 51,448 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 37,882 shares during the last quarter. Macquarie Group Ltd. purchased a new position in shares of Endologix in the 4th quarter worth approximately $46,000. Assenagon Asset Management S.A. purchased a new position in shares of Endologix in the 4th quarter worth approximately $55,000. Jane Street Group LLC lifted its stake in Endologix by 54.6% in the fourth quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 33,044 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in Endologix by 408.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 99,731 shares of the medical instruments supplier’s stock valued at $71,000 after purchasing an additional 80,100 shares during the last quarter.

Endologix stock traded down $0.10 during midday trading on Friday, reaching $5.79. The stock had a trading volume of 315,354 shares, compared to its average volume of 157,934. Endologix has a 12 month low of $5.20 and a 12 month high of $67.20. The firm has a market capitalization of $59.92 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. The company has a debt-to-equity ratio of 5.00, a current ratio of 2.03 and a quick ratio of 1.25.

Endologix (NASDAQ:ELGX) last issued its earnings results on Monday, February 25th. The medical instruments supplier reported ($2.10) EPS for the quarter, beating analysts’ consensus estimates of ($21.00) by $18.90. Endologix had a negative return on equity of 138.32% and a negative net margin of 50.94%. The business had revenue of $34.69 million during the quarter, compared to analyst estimates of $34.00 million. On average, sell-side analysts expect that Endologix will post -4.76 EPS for the current year.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

See Also: Front-End Load

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.